Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...

The Department of Veterans Affairs has started the process to designate multiple myeloma and acute and chronic leukemias as ...

Multiple myeloma is a type of cancer where plasma cells in bone marrow replicate out of control. Doctors use the acronym CRAB to diagnose myeloma by identifying four symptoms. The National Cancer ...

MMRF Multiple Myeloma Community Connect event to be held Nov. 14 ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant difference identified in the level of minimal residual disease (MRD) ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...